MarketWatch The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about ... and more »
GlobeNewswire (press release) The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about ... and more »
MarketWatch DIFICID, a macrolide antibacterial drug, was approved by the U.S. Food and Drug Administration on May 27, 2011, for the treatment of Clostridium difficile-associated diarrhea, or CDAD, in adults 18 years of age and older. Fidaxomicin also has received ...
Lifescience-online PYLERA is the only branded treatment option available that does not contain clarithromycin, a macrolide antibiotic. Utilization of macrolide antibiotics are believed to contribute to the growing rate of clarithromycin-resistant H. pylori. With the 10 ...
Patent Docs 7,906,519 ("Methods for Concomitant Administration of Colchicine and a Second Active Agent," issued March 15, 2011), 7,935,731 ("Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics," issued May 11, 2011), 8,093,298 (same ... and more »
